Sjögren’s syndrome is a serious autoimmune disease that can cause serious eye and vision problems due to reduced tear production.

A phase I trial with direct injection of ASCs into the lacrimal gland has proven safety and efficacy. Based on these data the first of 40 planned patients was enrolled and treated with ASCs February 2021 in the double-blind placebo-controlled phase II study in patients with tear gland malfunction (Aqueous Deficient Dry Eye Disease, Sjögren’s syndrome).